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In a previous study in experimental Klebsiella pneumoniae pneumonia, the therapeutic potential of cipro-
floxacin was significantly improved by encapsulation in polyethylene glycol-coated (“pegylated”) long-circu-
lating (STEALTH) liposomes. Pegylated liposomal ciprofloxacin in high doses was nontoxic and resulted in
relatively high and sustained ciprofloxacin concentrations in blood and tissues, and hence an increase in the
area under the plasma concentration-time curve (AUC). These data correspond to data from animal and
clinical studies showing that for fluoroquinolones the AUC/MIC ratio is associated with favorable outcome in
serious infections. Clinical failures and the development of resistance are observed for marginally susceptible
organisms like Pseudomonas aeruginosa and for which sufficient AUC/MIC ratios cannot be achieved. In the
present study the therapeutic efficacy of pegylated liposomal ciprofloxacin was investigated in two rat models
of Pseudomonas aeruginosa pneumonia. In the acute model pneumonia developed progressively, resulting in a
rapid onset of septicemia and a high mortality rate. Ciprofloxacin twice daily for 7 days was not effective at
doses at or below the maximum tolerated dose (MTD). However, pegylated liposomal ciprofloxacin either at
high dosage or given at low dosage in combination with free ciprofloxacin on the first day of treatment was fully
effective (100% survival). Obviously, prolonged concentrations of ciprofloxacin in blood prevented death of the
animals due to early-stage septicemia in this acute infection. However, bacterial eradication from the left lung
was not effected. In the chronic model, pneumonia was characterized by bacterial persistence in the lung
without bacteremia, and no signs of morbidity or mortality were observed. Ciprofloxacin administered for 7
days at the MTD twice daily resulted in killing of more than 99% of bacteria in the lung; this result can also
be achieved with pegylated liposomal ciprofloxacin given once daily. Complete bacterial eradication is never
observed.
Many in vitro studies as well as studies in animal models of
infection and human infections have investigated the efficacy of
fluoroquinolones. The area under the plasma concentration-
time curve (AUC) and the peak plasma drug concentration,
both in relation to the MIC of the pathogen, have been dem-
onstrated to be of primary importance for successful outcome
(33). For example, in several clinical trials in patients with
nosocomially acquired pneumonia, a 24-h AUC/MIC ratio of
at least 100 to 125 (14, 15, 19) or a peak plasma drug concen-
tration/MIC ratio of 10 or more (26) was closely linked to
clinical and microbiological cure in seriously ill patients treated
with intravenous ciprofloxacin. Most treatment failures with
ciprofloxacin were a consequence of high MIC, low AUC, or
both. A peak plasma drug concentration/MIC ratio of 10 or 20
has been shown both in vitro and in vivo to prevent the emer-
gence of resistant mutants during therapy with fluoroquinolo-
nes.
These observations in clinical studies are supported by data
obtained in in vitro pharmacokinetic models in which bacteria
were exposed to changing concentrations of fluoroquinolones
mimicking human pharmacokinetics (11, 13, 17, 20). A number
of studies in animal models of infection also revealed that the
AUC/MIC ratio was the most important predictor of thera-
peutic efficacy for fluoroquinolones (10, 19). The difficulty lies
in achieving AUC/MIC ratios of 125 to 250 in serious infec-
tions caused by pathogens such as Staphylococcus and Pseudo-
monas species that are only marginally susceptible to fluoro-
quinolones (MICs of 0.5 g/ml and above). The drugs may
need to be administered in relatively high doses, which might
prove to be toxic. As a result, treatment failure frequently
occurs.
In our previous study, improvement of the therapeutic po-
tential of ciprofloxacin was achieved by encapsulation in poly-
ethylene glycol (PEG)-coated (“pegylated”), long-circulating,
sustained-release (STEALTH) liposomes (5). The liposomes
had a PEG coating on the surface that provided a steric barrier
against opsonization, thereby reducing the interaction with the
mononuclear phagocyte system. Consequently, these “steri-
cally stabilized” liposomes exhibit a prolonged circulation time
(24). The pegylated liposomes protect the encapsulated cipro-
floxacin, which facilitates use of high doses of the drug without
toxic side effects. Administration of ciprofloxacin in the pegy-
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lated liposomal form resulted in delayed ciprofloxacin clear-
ance and increased and prolonged ciprofloxacin concentra-
tions in blood and tissues, thereby increasing the AUC (5). In
our rat model of unilateral pneumonia caused by Klebsiella
pneumoniae (MIC of ciprofloxacin, 0.1 g/ml) the therapeutic
efficacy of pegylated liposomal ciprofloxacin was superior to
that of ciprofloxacin in the free form. When administered in
the liposomal form, lower daily doses of ciprofloxacin were
effective. Pegylated liposomal ciprofloxacin was well tolerated
in relatively high doses, permitting once-daily administration
without loss in therapeutic efficacy.
The present study was performed to investigate whether the
superior therapeutic potential of pegylated liposomal cipro-
floxacin as observed in the rat model of K. pneumoniae pneu-
monia (5) could also be obtained in difficult-to-treat infection
caused by Pseudomonas aeruginosa with moderate susceptibil-
ity to ciprofloxacin. We developed two models of P. aeruginosa
infection: an acute pneumonia-septicemia and a chronic P.
aeruginosa pneumonia in rats. In the acute model, pneumonia
developed progressively, resulting in a rapid onset of septice-
mia and death of almost all animals. In the second model,
chronic pneumonia was characterized by persistence of P.
aeruginosa in the left lung without bacteremia. The course of
infection revealed no signs of morbidity or mortality.
MATERIALS AND METHODS
Animals. Female RP/AEur/RijHsd strain albino rats (age, 18 to 25 weeks;
body weight, 185 to 225 g; Harlan, Horst, The Netherlands) with a specified
pathogen-free status were used. The experiments were approved by the ethical
committee of the Erasmus University Medical Center Rotterdam.
Bacteria. A mucoid strain of Pseudomonas aeruginosa, originally isolated from
a patient with cystic fibrosis, was used to infect the rats. The MIC and minimum
bactericidal concentration of ciprofloxacin for this strain were 0.4 and 0.8 g/ml,
respectively, as determined by the tube dilution test in Mueller-Hinton broth
supplemented with Ca2 (25 mg/liter) and Mg2 (12.5 mg/liter) (Difco Labora-
tories, Detroit, Mich.).
Infection models of acute P. aeruginosa pneumonia-septicemia and chronic P.
aeruginosa pneumonia. A left-sided pneumonia was induced, as described in
detail elsewhere (2), by intubation of the left primary bronchus followed by
inoculation of the left lung with 20 l of a saline suspension of P. aeruginosa
bacteria in the logarithmic phase of growth. To establish the acute P. aeruginosa
pneumonia-septicemia, 7  108 viable P. aeruginosa bacteria were inoculated
into the left lung. To establish the chronic P. aeruginosa pneumonia, the inocu-
lum consisted of 2  108 viable P. aeruginosa bacteria. Inocula were prepared as
follows: P. aeruginosa was cultured in Todd-Hewitt broth (Difco Laboratories) at
37°C for 14 h. This bacterial suspension (end-log phase) had an optical density at
660 nm of 0.23 to 0.24. Bacteria were washed and concentrated appropriately by
centrifugation for 10 min at 10,000  g at 4°C.
Blood samples were obtained by retro-orbital bleeding under CO2 anesthesia
to assess the course of infection at various intervals after inoculation. Then,
animals were sacrificed, the weight of the infected left lung was determined, and
the left and right lungs were homogenized (VirTis homogenizer; Virtis,
Gardiner, N.Y.) in 20 ml of phosphate-buffered saline for 30 s at 10,000 rpm.
Tissue homogenates and blood were serially diluted and plated on tryptone soy
agar (Unipath Ltd., Basingstoke, United Kingdom). After dilution, the remain-
ing homogenates were subjected to the pour plate method, and all remaining
blood volume (around 4 to 5 ml) was cultured. Plates were incubated overnight
at 37°C.
Liposomes. Polyethylene-glycol-coated liposomes containing ciprofloxacin
consisted of the PEG 2000 derivative of distearoylphosphatidylethanolamine,
hydrogenated soybean phosphatidylcholine, and cholesterol in a molar ratio of
5:50:45. Pegylated liposomes were kindly supplied by ALZA Corporation
(Mountain View, Calif.). Mean particle size was determined by dynamic light
scattering (4700 system; Malvern Instruments, Malvern, United Kingdom). Li-
posomes containing ciprofloxacin, used in the model of acute P. aeruginosa
pneumonia-septicemia, had a particle size of 126  11 nm and contained 322 
52 g of ciprofloxacin/mol of total lipid (means  standard deviations [SD] of
five preparations). Liposomes containing ciprofloxacin used in the model of
chronic P. aeruginosa pneumonia had a particle size of 107  7.2 nm and
contained 256  51 g of ciprofloxacin/mol of total lipid (mean  SD of 10
preparations).
Antimicrobial treatment. In the model of acute P. aeruginosa pneumonia-
septicemia, antibiotic was administered as bolus intravenous injections over a
1-min period via the tail vein. Treatment was started 16 h after bacterial inoc-
ulation of the left lung and continued for 7 days or was given for only 1 day at the
start of treatment. Ciprofloxacin in the free form (CIP) in 5% glucose, pH 7.0,
or in the pegylated liposomal form (PL Cipro) in 10% sucrose–10 mM histidine,
pH 6.5, was given. Various dosages ranging from 20 to 160 mg of CIP or PL
Cipro/kg of body weight/day alone or in combination were administered (n  5
to 15 per dosage). The injection frequency was 12 h. Therapeutic efficacy was
assessed by rat survival at day 21 after bacterial inoculation.
In the model of chronic P. aeruginosa pneumonia, treatment with CIP or PL
Cipro was started 4 days after inoculation of the left lung and continued for 3 or
7 days. Various dosages ranging from 40 to 160 mg/kg/day were administered (n
 4 to 9 per dosage). The injection frequency was 12 or 24 h. Therapeutic efficacy
was assessed by quantification of bacterial numbers in the left lung, right lung,
and blood.
To prevent carryover of ciprofloxacin or liposomal ciprofloxacin (if still present
in the lung) to the subculture plates, charcoal (Carbomix; Norit N.V., Amers-
foort, The Netherlands) was added to the homogenate suspensions (15 g/100 ml)
before the homogenization procedure for immediate inactivation of ciprofloxa-
cin.
In both models, the susceptibility of the P. aeruginosa to ciprofloxacin was
evaluated in rats that died and in rats sacrificed early.
Toxicity. Acute toxicity was characterized in terms of seizures, irritability, and
an apparent dazed state. Chronic long-term toxicity was assessed in terms of a
significant change in renal or hepatic function. Renal function abnormalities
were determined by measuring blood urea nitrogen and serum creatinine; he-
patic function abnormalities were detected by measuring the serum aspartate
aminotransferase and alanine aminotransferase by established tests (Merck Di-
agnostica, Darmstadt, Germany).
Concentrations of ciprofloxacin in tissue after administration of CIP or PL
Cipro. CIP or PL Cipro at the maximal tolerated dose (MTD) (40 or 160 mg/kg,
respectively, as a single dose) was injected into rats with chronic P. aeruginosa
pneumonia 4 days after bacterial inoculation. Total ciprofloxacin concentrations
in infected left lung and right lung tissues were measured at 1 h after injection.
Rats were sacrificed, and then the infected left lung and right lung were removed
and homogenized in 20 ml of phosphate-buffered saline (4°C). Tissue homoge-
nates from rats that received PL Cipro were incubated in 0.1% Triton X-100
(Janssen Chimica, Geel, Belgium) for 30 min at 25°C to disrupt the liposomes in
order to determine total (free plus encapsulated) drug concentrations. In the
supernatants (obtained after centrifugation of the samples for 5 min at 12,000 
g) ciprofloxacin concentrations were determined by the agar diffusion test using
a diagnostic sensitivity test agar (Oxoid, Basingstoke, United Kingdom) with
Escherichia coli as the indicator organism and standards ranging from 0.1 to 1.6
g of ciprofloxacin/ml in 5% glucose (5, 6). The strain is susceptible to 0.025 g
of ciprofloxacin per ml. Samples of 100 l were assayed in large agar plates
containing wells. The coefficient of variation of 15 determinations of solutions
containing 0.1 to 1.6 g of ciprofloxacin per ml was 1 to 3%.
Antibacterial effect of ciprofloxacin against P. aeruginosa in vitro. Ciprofloxa-
cin concentrations of 0.5, 1.0, and 2.0 g/ml were used with final inocula of 107
CFU/ml of logarithmic-phase P. aeruginosa or 2.2  109 CFU/ml of stationary-
phase P. aeruginosa. Cultures in Mueller-Hinton broth (Difco Laboratories)
supplemented with Ca2 (25 mg/liter) and Mg2 (12.5 mg/liter) were incubated
at 37°C on a shaker for 3 h. Bacterial survival was then determined over 6 h by
plating 10-fold serial dilutions of the washed specimens on tryptone soy agar
plates.
Statistical evaluation. In the model of acute P. aeruginosa pneumonia-septi-
cemia, survival rates were compared using the log-rank test. In the model of
chronic P. aeruginosa pneumonia, results from quantitative cultures were com-
pared using one-way analysis of variance corrected for multiple comparisons
using the Bonferroni method.
RESULTS
Rat model of acute P. aeruginosa pneumonia-septicemia. An
inoculum of 7  108 P. aeruginosa bacteria was used to estab-
lish the left lung infection. The resulting infection was charac-
terized by a rapid increase in bacterial numbers in the left lung
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up to sixfold within 16 h after bacterial inoculation (Table 1).
A small variation between the individual animals was observed
in quantitative cultures of P. aeruginosa from the infected left
lung. The acute infectious process in the left lung was reflected
by a substantial increase in the weight of the left lung up to
fourfold, compared with the normal weight of the uninfected
left lungs (0.3 to 0.4 g). The infection rapidly spreads to the
right lung. Three of nine rats developed positive blood cul-
tures.
At 24 h after inoculation, bacterial numbers in the left lung,
the weight of the left lung, and bacterial numbers in the right
lung had further increased. Four of seven rats developed sep-
ticemia. The course of infection revealed a high mortality rate:
Most rats died between 24 and 48 h after bacterial inoculation.
Three of 27 untreated rats (11%) survived.
Therapeutic efficacy of PL Cipro versus that of CIP in rats
with acute P. aeruginosa pneumonia-septicemia. In untreated
rats, acute pneumonia developed progressively, resulting in a
rapid onset of septicemia and death of most of the animals,
mortality being 89% (Table 2).
At 16 h after bacterial inoculation, the time that in untreated
rats the bacterial numbers in the left lung had increased ap-
proximately sixfold and three of nine rats had developed sep-
ticemia, antimicrobial treatment with CIP and PL Cipro alone
or in combination was started. Results of treatment are shown
in Table 2. Treatment with CIP alone at dosages below the
MTD was not effective: Survival of rats was not significantly
increased compared with controls at a CIP dosage of 40 mg/
kg/day twice daily. At a CIP dosage of 80 mg/kg/day twice daily,
survival of rats was increased (although not significantly) to
38%. However, acute toxicity following administration of CIP
was observed in 8 of 15 rats. When a single 40-mg/kg dose of
PL Cipro was added on the first day of the 7-day treatment
with CIP at 40 mg/kg/day twice daily, toxic side effects were not
observed. This dosage regimen resulted in 80% survival, a
significant (P  0.03) increase over that in controls.
Treatment with PL Cipro alone at 40 mg/kg/day twice daily
in two divided doses did not significantly increase rat survival.
Increasing the daily dosage of PL Cipro did not result in toxic
side effects, and 100% survival was achieved (P  0.0001 com-
pared with controls) when PL Cipro was administered at 160
mg/kg/day twice daily. A significant increase in the survival was
also effected by the addition of CIP only at the first day of
treatment to a 7-day treatment of PL Cipro at 40 mg/kg/day
twice daily: 100% survival was obtained when CIP at 40 mg/kg
was added on the first day (P 0.0001). Toxic side effects were
not observed with this dosage schedule. In the surviving rats
the bacterial numbers in the left lung were determined at day
21. P. aeruginosa organisms were always cultured, numbers
ranging from 102 to 107 cells.
Previous experiments showed that the administration of pla-
cebo liposomes with a mean diameter of 105  6.4 nm had no
effect on the survival of rats.
The ciprofloxacin susceptibility of P. aeruginosa recovered
from dead or sacrificed rats was never changed compared with
that of the inoculated bacteria.
Rat model of chronic P. aeruginosa pneumonia. To establish
the left lung infection, P. aeruginosa was used at an inoculum of
2  108 bacteria. The resulting infection was characterized by
bacterial persistence in the left lung for at least 11 days (Table
3). A small variation between individual animals was seen.
Bacterial persistence in the right lung at a relatively low level
was also observed. Blood cultures of rats were always negative
from day 4. The course of infection revealed no signs of mor-
bidity or mortality.
Therapeutic efficacy of PL Cipro versus that of CIP in rats
TABLE 1. Course of infection in rats with acute P. aeruginosa
pneumonia-septicemiaa
Time (h)
after
inoculation
Mean wt (g)
of left lung
 SD
Mean log no. of bacteria
 SD in:
Median log
no. of bacteria/
ml of blood
(range)Left lung Right lung
16 1.3  0.15 9.6 0.24 5.9  1.4 0 (0–2.6)
24 1.9  0.30 10.6 0.2 7.4  0.84 2.6 (0–3.5)
a Left-sided pneumonia was produced by inoculation of the rats with 7  108
CFU of P. aeruginosa. At various intervals after inoculation, rats were sacrificed,
the weight of the infected left lung was determined, and quantitative cultures of
infected organs were performed. In untreated infection all rats died between 24
and 48 h after bacterial inoculation. Data are based on results for seven to nine
rats.
TABLE 2. Therapeutic efficacy of treatment at 12-h intervals of
rats with acute P. aeruginosa pneumonia-septicemiaa
Treatment % Survival (no.)
None........................................................................................... 11 (27)
CIP
40 (7) ...................................................................................... 17 (12)
80 (7) ...................................................................................... 38b (15)
PL Cipro
40 (7) ...................................................................................... 25 (12)
80 (7) ...................................................................................... 73 (11)
160 (7) ....................................................................................100 (7)
CIP  PL Cipro
40 (7)  40 (1) ...................................................................... 80 (5)
20 (1)  40 (7) ...................................................................... 60 (5)
40 (1)  40 (7) ......................................................................100 (5)
a Treatment is given as dosage (milligrams per kilograms per day), with du-
ration (in days) shown in parentheses. Treatment was started at 16 h after
inoculation of P. aeruginosa into the left lung and continued for 7 days or was
administered only 1 day at the start of treatment. Various doses of CIP or PL
Cipro alone or in combination were administered. The injection frequency was
12 h. Survival of rats was assessed for 21 days.
b Toxic side effects (acute toxicity) were observed in 8 of 15 rats.
TABLE 3. Course of infection in rats with chronic
P. aeruginosa pneumonia
Time
(days)
after
inoculation
Mean wt (g)
of left lung
 SD
Mean log no. of bacteria
 SD in:
Median log
no. of bacteria/
ml of blood
(range)Left lung Right lung
1 0.90  0.14 8.2 0.51 2.7  0.86 0 (0–1.6)
4 1.6  0.25 7.8 0.37 3.5  0.39 0
7 1.1  0.30 8.2 0.72 2.2  1.4 0
11 0.78  0.09 7.1 0.24 3.3  1.38 0
a Left-sided pneumonia was produced by inoculation of the rats with 2  108
CFU of P. aeruginosa. At various intervals after inoculation, rats were sacrificed,
the weight of the infected left lung was determined, and quantitative cultures of
infected organs were performed. Data are based on results for nine rats.
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with chronic P. aeruginosa pneumonia. At 4 days after bacterial
inoculation, the time that in untreated rats the bacterial num-
bers in the left lung and right lung were 7.8  0.37 and 3.5 
0.39, respectively (Fig. 1 and 2), and blood was sterile, antimi-
crobial treatment with CIP or PL Cipro was started. Results of
treatment are shown in Fig. 1 and 2. A 3-day treatment with
CIP at 80 mg/kg/day twice daily (MTD) was not effective:
bacterial numbers in the left lung (7.3  0.6) were not signif-
icantly decreased compared with bacterial numbers at the start
of treatment (Fig. 1). Similarly, a 3-day treatment with PL
Cipro at 160 mg/kg/day (MTD) twice daily was not effective:
Although the bacteria in the right lung were killed, bacterial
numbers in the left lung were 6.7  0.8. Blood cultures of rats
treated with CIP or PL Cipro remained negative.
Increasing the length of treatment up to 7 days resulted in
therapeutic efficacy (Fig. 2). At all dosage schedules of CIP and
PL Cipro tested, bacterial numbers in the left lung were sig-
nificantly (P 0.003) decreased compared with bacterial num-
bers at the start of treatment. Significant bacterial killing in the
left lung of 99% could be achieved with CIP at the MTD
provided it was administered twice daily, i.e., at a dosage of 80
mg/kg/day. Bacterial numbers in the left lung were 5.0 0.5 (P
 0.001). Right lungs were sterile. Once-daily administration
of CIP at 40 mg/kg/day did not result in99% bacterial killing:
bacterial numbers in the left lung were 6.9  0.2, and right
lungs were not sterile. PL Cipro at 80 mg/kg/day once daily also
effected 99% killing of bacteria in the left lung and steriliza-
tion of the right lung. Bacterial numbers in the left lung were
4.8  0.5 (P  0.001). Complete bacterial eradication in the
left lung could not be achieved even with intensive dosage
schedules of PL Cipro at 160 mg/kg/day (MTD) administered
either twice daily or once daily. Under these dosage regimens
bacterial numbers in the left lung were 5.0  0.8 (P  0.001)
and 5.3  0.7 (P  0.001), respectively.
The administration of placebo liposomes had no effect on
the infectious process: at day 7 after bacterial inoculation the
weight of the left lung and the bacterial loads in the left lung
and right lung and blood were not significantly different com-
pared to values for untreated controls.
The ciprofloxacin susceptibility of P. aeruginosa recovered
from dead or sacrificed rats was never changed compared with
that of the inoculated bacteria.
Toxic side effects. The intravenous administration of CIP
and PL Cipro as a bolus injection results in higher concentra-
tions in serum than observed in humans in whom it is admin-
istered as bolus infusion. This may increase the acute toxicity
compared to that observed in humans. The MTD for CIP was
20 mg/kg/dose in the severely ill rats with acute P. aeruginosa
pneumonia-septicemia. At higher doses, acute toxicity was ob-
served shortly after the first dose. In rats with chronic P. aerugi-
nosa pneumonia, the MTD for CIP was 40 mg/kg/dose. Ad-
ministration of PL Cipro up to a dosage of 160 mg/kg/day did
not result in acute toxic side effects in the models of acute or
chronic P. aeruginosa infection. In addition, long-term toxicity
was not observed. Dosages of PL Cipro of 160 mg/kg/dose
were not tested because of the reported side effects of the
FIG. 1. Therapeutic efficacy of treatment at 12-h intervals for 3
days of rats with chronic P. aeruginosa pneumonia. Treatment was
started at 4 days after bacterial inoculation in the left lung (n  4 to 9
per dosage). At the end of treatment (7 days after bacterial inocula-
tion), rats were sacrificed, and quantitative cultures of left lung, right
lung, and blood were performed. Results are expressed as means SD
(error bars).
FIG. 2. Therapeutic efficacy of treatment at 12- or 24-h intervals
for 7 days of rats with chronic P. aeruginosa pneumonia. Treatment was
started at 4 days after bacterial inoculation in the left lung (n  4 to 8
per dosage). At the end of treatment (11 days after bacterial inocula-
tion), rats were sacrificed, and quantitative cultures of left lung, right
lung, and blood were performed. Results are expressed as means SD
(error bars). Significant differences against the bacterial numbers at
the start of treatment (day 4) are noted (**, P  0.001; *, P  0.003).
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relatively high lipid doses that can result from the formulation
(4).
Concentrations of ciprofloxacin in tissue after administra-
tion of CIP or PL Cipro at the MTD in rats with chronic P.
aeruginosa pneumonia. Total concentrations of ciprofloxacin
(free plus liposome-encapsulated) are presented in Table 4. At
1 h after administration of CIP at 40 mg/kg (MTD) as a single
dose, recovery of ciprofloxacin from infected left lung and right
lung was relatively low, at 0.4 and 0.3% of the injected dose,
respectively. Administration of PL Cipro at 160 mg/kg (MTD)
as a single dose resulted in increased total ciprofloxacin con-
centrations in the infected left lung and right lung. At 1 h after
injection, ciprofloxacin concentrations in infected left lung and
right lung were 19- and 31-fold increased, respectively, com-
pared with the concentrations after administration of CIP at its
MTD.
Effect of ciprofloxacin against P. aeruginosa in broth in re-
lation to bacterial growth rate. Logarithmically growing P.
aeruginosa organisms in broth were killed by ciprofloxacin de-
pendent on the concentrations used. When the bacteria were
in the stationary phase of growth, ciprofloxacin was still able to
kill the bacteria effectively. Within 3 h of incubation, cipro-
floxacin at the concentration of 0.5 g/ml killed logarithmically
growing bacteria and stationary-phase bacteria efficiently, and
the log CFU was 2.1 and 2.7, respectively. At the highest
concentration, 2 g of ciprofloxacin per ml, bacterial killing
was increased, and the log CFU was 4.2 and 3.9, respectively.
DISCUSSION
In previous studies in our laboratory antimicrobial agents
were encapsulated in PEG-coated long-circulating liposomes
in order to achieve different pharmacokinetics of the agents (2,
3, 5, 27–30). When ciprofloxacin is encapsulated these lipo-
somes act as a sustained-release microreservoir (5). The AUC
at 24 h for ciprofloxacin, when administered at similar doses of
20 mg/kg in the liposome-encapsulated (once daily) or free
(twice daily) form, are 900 and 74 g·h/ml, respectively. In the
rat model of K. pneumoniae pneumonia, it was demonstrated
that the increased AUC of ciprofloxacin led to an increased
therapeutic efficacy (5). These data agree with the findings of
Drusano et al. obtained in a neutropenic rat model of P.
aeruginosa sepsis, in which the relationship between the plasma
concentration-time profile and therapeutic efficacy (survival)
of lomefloxacin was investigated (10). AUC/MIC ratios as well
as peak concentration in plasma/MIC ratios appeared to be
associated with favorable outcome. The clinical relevance of
these pharmacodynamic parameters has been examined and
confirmed in clinical trials of fluoroquinolones in seriously ill
patients (14, 15, 19, 25, 26).
In clinical practice, an optimal dose regimen is particularly
important for infections due to microorganisms such as P.
aeruginosa and Staphylococcus aureus for which the MICs of
most fluoroquinolones are at or slightly below the breakpoint
for susceptibility and for which selection of bacterial resistance
has been associated with failure of treatment (25). Sufficient
AUC/MIC ratios cannot be achieved (14). Relatively high
doses of fluoroquinolones should be avoided due to toxic side
effects. The question is whether encapsulation of fluoroquino-
lones in PEG-coated liposomes that results in a low toxicity
profile and relatively high, sustained concentrations in plasma
can compensate for the relatively high MIC, resulting in an
adequate AUC/MIC ratio. This was investigated in the present
study.
We developed two models of P. aeruginosa infection in rats
and compared the therapeutic efficacies of PL Cipro and CIP.
The susceptibility of the P. aeruginosa strain, a mucoid strain
and clinical isolate from a patient with cystic fibrosis, was
relatively low (MIC  0.5 g/ml). In the model of acute P.
aeruginosa pneumonia-septicemia, initially the infection in the
lung developed rapidly, resulting in septicemia at an early stage
and a high mortality rate. In the model of chronic P. aeruginosa
pneumonia, bacterial persistence in the lung was observed over
a prolonged period, which did not lead to mortality of rats.
These infection models have totally different characteristics
and are both clinically relevant.
The MTD of CIP in the severely ill rats with acute P. aerugi-
nosa pneumonia-septicemia was 20 mg/kg/dose, which was
twofold lower than the MTD in rats with chronic P. aeruginosa
pneumonia. However, in both models PL Cipro was well tol-
erated in high doses up to 160 mg/kg.
In the acute P. aeruginosa pneumonia-septicemia, CIP was
not effective whereas PL Cipro in relatively high doses which
are well tolerated was effective in all rats. Addition of PL Cipro
at low dosage on the first day of treatment with CIP at the
MTD resulted in increased therapeutic efficacy without toxic-
ity. Addition of CIP at the MTD on the first day of treatment
with PL Cipro at low dosage also effected therapeutic efficacy
in all rats without toxic side effects. As the early onset of
septicemia in the acute P. aeruginosa infection is the primary
cause of death in these rats before pneumonia is established,
the sustained release of ciprofloxacin from the liposomes re-
sulting in prolonged concentrations in the blood is of major
importance for survival of the animals. Sufficiently high and
sustained concentrations of ciprofloxacin in plasma are needed
due to the moderate susceptibility of the P. aeruginosa strain.
This can be achieved with a high dosage of PL Cipro, or with
a low dosage of PL Cipro in combination with CIP at the start
of treatment to increase the bioavailability of ciprofloxacin in
the early phase of treatment. These treatment schedules, al-
though resulting in animal survival, did not effect bacterial
eradication in the lung.
In the chronic P. aeruginosa pneumonia, a treatment period
of 3 days using CIP or PL Cipro at their respective MTDs had
no effect. After 7 days of treatment, however, both CIP and PL
Cipro effected a significant decrease in bacterial count in the
chronically infected left lung compared with that at the start of
TABLE 4. Concentrations of total ciprofloxacin (free plus
liposome-encapsulated) in infected lung at 1 h after administration
in rats with chronic P. aeruginosa pneumoniaa
Lung
Mean concn (g/g of tissue)  SD (% of injected
dose)
CIP PL Cipro
Left 23.8  6.5 (0.4) 459  245 (2.0)
Right 38.8  22.3 (0.3) 1,207  268 (2.7)
a CIP (40 mg/kg) or PL Cipro (160 mg/kg) was injected as a single dose at 4
days after inoculation of rats with P. aeruginosa.
b Data are based on results for five rats.
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treatment. If given twice daily CIP at its MTD resulted in
killing of99% of the bacteria, an effect also achieved with PL
Cipro administered once daily. In this respect, PL Cipro is
superior to CIP. Bacterial eradication was never obtained,
even after intensive treatment with PL Cipro. Although cipro-
floxacin in the liposomal form can be administered in a rela-
tively high dosage, resulting in a 19-fold increase in concentra-
tion of ciprofloxacin at the infected site compared to
administration in the free form, this concentration seems to be
insufficient for killing all P. aeruginosa organisms.
Studies by other investigators using non-PEG-coated lipo-
somal fluoroquinolones in models of intracellular infections
revealed an increase in therapeutic effect as a result of liposo-
mal encapsulation (8, 9, 21, 32). To what extent infected tissue
targeting of the liposomal antibiotics also contributes to the
increased therapeutic efficacy in these animal models was not
investigated. Other studies showed an increased intracellular
penetrating capacity of liposomal fluoroquinolones compared
with drugs in the free form (22, 23). Leitzke et al. compared
drug concentrations in a model of Mycobacterium avium infec-
tion in lung and liver of mice after administration of amikacin
or ciprofloxacin in the free or liposomal form (18). Liposomal
encapsulation of amikacin, but not of ciprofloxacin, resulted in
sustained high drug levels in infected tissues. These compara-
tive data agree with observations obtained for gentamicin and
ciprofloxacin in our model of K. pneumoniae pneumonia (5,
30).
Also, in patients with respiratory tract infections due to P.
aeruginosa, in spite of intensive treatment with ciprofloxacin
bacterial persistence has been described by various authors (1,
7, 12, 16, 31). Successful eradication of bacteria from lung
tissue chronically infected with P. aeruginosa is probably ham-
pered by various factors. The mucoid, alginate-producing P.
aeruginosa bacteria form microcolonies that may impair anti-
biotic penetration. In addition, the bacteria may be at a low
metabolically active state inside the microcolonies, which may
further diminish antibiotic killing capacity. However, based on
their mode of action, the fluoroquinolones are expected to be
active against bacteria in a low metabolically active state, which
is also demonstrated in the present study, showing the concen-
tration-dependent killing of ciprofloxacin in vitro against P.
aeruginosa in the logarithmic phase as well as stationary phase
of growth. Another factor contributing to the failure of treat-
ment to fully eradicate the bacteria may be the intracellular
localization of a minority of the P. aeruginosa organisms. It is
not known to what extent the ciprofloxacin concentrations
measured in the infected tissue reflect interstitial concentra-
tions or intracellular concentrations. For further improvement
of therapeutic efficacy in chronic P. aeruginosa infection, the
application of fluoroquinolone-containing liposomes that re-
tain their content during circulation, thereby effecting target-
ing of the drugs to the site of infection, may be of major
importance.
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